Structure via PubChem · Public domain (PubChem)
Mozavaptan
Sign in to saveAlso known as OPC 31260, OPC-31260, OPC31260
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
Chemical data
- Formula
- C27H29N3O2
- Molecular weight
- 427.5 g/mol
- IUPAC name
- N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide
- SMILES
- CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
- InChIKey
- WRNXUQJJCIZICJ-UHFFFAOYSA-N
- XLogP
- 4.5
- Polar surface area
- 52.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2006
- Admin. routes
- oral
via ChEMBL · EBI
Research
160 papers- Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan.Toxicology letters · 2023
- UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats.Bioanalysis · 2018
- Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.Japanese journal of clinical oncology · 2011
- [Vasopressin receptor antagonists: the vaptans].Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion · 2010
- Non-peptide arginine-vasopressin antagonists: the vaptans.Lancet (London, England) · 2008
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 427.225977
Show 3 more facts
- chemical formula
- C₂₇H₂₉N₃O₂
- canonical SMILES
- CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
- Commons category
- Mozavaptan
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
==References==
Excerpted from Wikipedia’s “Mozavaptan” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0